| Literature DB >> 31190759 |
Jennifer Scheel1, Katharina Schieber1, Sandra Reber1, Sabine Jank2, Kai-Uwe Eckardt2, Franziska Grundmann3, Frank Vitinius4, Martina de Zwaan5, Anna Bertram6, Yesim Erim1.
Abstract
Introduction: Though psychosocial well-being and quality of life generally improve after transplantation, a relevant proportion of patients suffers from psychosocial problems. Further analysis of the psychological coping after kidney transplantation is needed to identify patients at risk. The aim of this study was to examine the psychological response after kidney transplantation and its associations with health-related quality of life and immunosuppressant medication adherence. Materials and methods: The coping process after kidney transplantation was investigated with the Transplant Effects Questionnaire (TxEQ; subscales: worry, guilt, disclosure, adherence, responsibility) in 267 adult kidney transplant recipients ≥12 months post-transplantation. Furthermore, perceived health-related quality of life, self-reported immunosuppressant medication adherence, and sub-therapeutic immunosuppressant trough levels as biological markers of adherence were assessed.Entities:
Keywords: Transplant Effects Questionnaire; adherence; health-related quality of life; immunosuppressant trough levels; kidney transplantation; psychological processing
Year: 2019 PMID: 31190759 PMCID: PMC6526178 DOI: 10.2147/PPA.S194254
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Comparison of TxEQ subscale scores by sex
| TxEQ subscales | Females (n=93) | Males (n=174) | Effect size (r) | ||
|---|---|---|---|---|---|
| Worry | M ± SD (range) | 2.9±0.8 (1.3–4.7) | 2.8±0.8 (01.0–4.7) | Not significant | 0.1 |
| Guilt | M ± SD (range) | 2.0±0.6 (1.0–3.4) | 1.9±0.7 (1.0–4.0) | Not significant | 0.1 |
| Disclosure | M ± SD (range) | 4.4±0.7 (2.3–5.0) | 4.4±0.7 (1.7–5.0) | Not significant | 0.0 |
| Responsibility | M ± SD (range) | 2.7±1.0 (1.0–4.5) | 2.9±1.1 (1.0–5.0) | Not significant | −0.1 |
| Adherence | M ± SD (range) | 4.4±0.6 (2.0–5.0) | 4.4±0.6 (1.6–5.0) | Not significant | 0.0 |
Abbreviations: M, mean; SD, Standard Deviation; TxEQ, Transplant Effects Questionnaire.
Descriptive data of the TxEQ subscales and their correlative associations
| TxEQ subscales | |||||||
|---|---|---|---|---|---|---|---|
| Worry | Guilt | Disclosure | Responsibility | Adherence | |||
| Worry | M ± SD (range) | 2.8±0.8 (1.0–4.7) | 0.4** | −0.3** | 0.5** | −0.1 | |
| Guilt | M ± SD (range) | 1.9±0.7 (1.0–4.0) | −0.3** | 0.5** | −0.2** | ||
| Disclosure | M ± SD (range) | 4.4±0.7 (1.7–5.0) | −0.2** | 0.3** | |||
| Responsibility | M ± SD (range) | 2.8±1.0 (1.0–5.0) | −0.1 | ||||
| Adherence | M ± SD (range) | 4.4±0.6 (1.6–5.0) | |||||
Notes: **p≤0.001; *p<0.05.
Abbreviations: M, mean; SD, Standard Deviation; TxEQ, Transplant Effects Questionnaire.
Descriptive data of perceived health-related quality of life, self-reported immunosuppressant medication nonadherence, and sub-therapeutic immunosuppressant trough levels and their correlative associations with the TxEQ subscales
| TxEQ subscales | |||||||
|---|---|---|---|---|---|---|---|
| Worry | Guilt | Disclosure | Responsibility | Adherence | |||
| Nonadherence (BAASIS©), dichotomous | Yes: n, % | 87 (33.3%) | 0.0 | 0.0 | −0.0 | −0.1 | −0.4** |
| Nonadherence (BAASIS©), continuous | M ± SD (range) | 0.6±1.1 (0.0–6.0) | 0.0 | 0.0 | −0.1 | −0.1 | −0.4** |
| Percentage of sub-therapeutic immunosuppressant trough levels | M ± SD (range) | 40±30% (0–100) | 0.1* | 0.1 | −0.1 | 0.1 | 0.0 |
| Physical health-related quality of life(SF-12, PCS) | M ± SD (range) | 44.9±10.6 (15.7–67.7) | −0.1 | −0.1 | 0.1 | −0.0 | −0.0 |
| Mental health-related quality of life (SF12, MCS) | M ± SD (range) | 49.3±10.2 (19.6–66.5) | −0.3** | −0.3** | 0.3** | −0.1* | 0.1 |
Notes: **p≤0.001; *p<0.05.
Abbreviations: M, mean; SD, Standard Deviation; TxEQ, Transplant Effects Questionnaire.